Financial
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$24.6bn | +3.0% | US$4.7bn | US$3.6bn | Danaher group |
Products not yet catalogued.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
No adverse media involving Beckman Coulter found in HSH's search of the last 24 months.
Feb 2025: A medium-severity vulnerability (CVE-2025-0941) was published for Beckman Coulter Life Sciences' MET ONE 3400+ particle counter, which could store credentials in plain text in rare conditions. No breaches or regulator actions found. NHS DSPT status not yet checked.
Mar 2026: The FDA posted a Class 2 recall of one lot of Beckman Coulter MicroScan Neg MIC 56 panels, started by the firm in Jul 2025, owing to likely contamination in a test well.
Apr 2025: University Hospitals of North Midlands NHS Trust gave notice of a pathology managed service award to Beckman Coulter for its Leighton and Macclesfield sites; in Oct 2025 GOSH directly awarded it a £272k lab automation contract.
No competitors linked yet.